Phase 1 study of single-agent CC-292, a highly selective Bruton’s tyrosine kinase inhibitor, in relapsed or refractory chronic lymphocytic leukemia


Disclosures: J.R. Brown has served as a consultant for Celgene, Pharmacyclics, Roche/Genentech, Gilead, Infinity and Janssen. B.T. Hill has received honorarium from Celgene and Pharmacyclics. J.P. Sharman has received research funding from Celgene, and honorarium from Celgene for consulting and an advisory board. J.M. Foran has received research funding from Celgene. J.A. Burger has received research funding from Pharmacyclics and Gilead. K.R. Kelly has received honorarium from Celgene for a speakers bureau. S. Ma has provided consulting for Pharmacyclics and Gilead, and lecturing for Pharmacyclics/Janssen, Gilead, and Genetech. Y. Li is employed by Celgene. D.W. Pierce, E. Barnett, J. Marine, M. Miranda, and A. Azaryan are employed by Celgene and have stock ownership of Celgene. X. Yu is employed by Celgene. P. Nava-Parada has stock ownership of Celgene. J. Mei is employed by Celgene and has stock ownership of Celgene. No potential conflicts of interest were disclosed by the other authors.

Contributions: JRB, PNP, JM and DWP designed the research. JRB, WAH, BTH, JG, JPS, MTS, PMB, JMF, TPM, JAB, KRK, DM, SM, PNP, JM, DWP, and TJK performed the research. JRB, JM, EB, DWP, YL, PNP, MM, AA, XY, and JM analyzed the data. JRB wrote the initial draft of the paper and received comments and edits from all authors. All authors approved the final manuscript.